Skip to content

A study comparing polyethylene glycol solution with prucalopride versus polyethylene Glycol Solution with bisacodyl for colonoscopy preparation

A Comparative Study of 2-L Polyethylene Glycol Solution with Prucalopride versus 2-L Polyethylene Glycol Solution with Bisacodyl for Bowel Preparation in Colonoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033230
Enrollment
352
Registered
2021-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K639- Disease of intestine, unspecified Health Condition 2: K57- Diverticular disease of intestine Health Condition 3: K60- Fissure and fistula of anal and rectal regions Health Condition 4: K591- Functional diarrhea Health Condition 5: K64- Hemorrhoids and perianal venous thrombosis Health Condition 6: K580- Irritable bowel syndrome with diarrhea Health Condition 7: K589- Irritable bowel syndrome without diarrhea Health Condition 8: K50-K52- Noninfective enteritis and coliti

Interventions

Intervention1: 2-L Polyethylene Glycol Solution with Prucalopride: Patient should be on low fiber diet for 3days preceding colonoscopy. Split-dose regimen will be used for the prucalopride and PEG gro

Sponsors

Manjit Kanungo
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult (>=18 years) patients scheduled for colonoscopy will be recruited from the outpatient department of gastroenterology, Andhra medical college, Visakhapatnam.

Exclusion criteria

Exclusion criteria: 1. Known or suspected bowel obstruction or perforation 2. Acute exacerbation of inflammatory bowel disease 3. Toxic megacolon 4. History of colorectal resection 5. Compromised swallowing reflex or mental status 6. Significant gastroparesis or gastric outlet obstruction 7. Severe congestive heart failure (NYHA III/IV), recent acute MI or unstable angina (within 8 weeks) 8. Severe chronic renal failure (creatinine clearance 9. Pregnancy or lactation 10.H/O of hypersensitivity to any bowel cleansing agent 11.Chronic constipation ( week with or without laxative)

Design outcomes

Primary

MeasureTime frame
Efficacy of bowel preparationTimepoint: Proportion of patients having adequate bowel preparation will be assessed during colonoscopy by using Boston Bowel Preparation Scale (BBPS). Adequate bowel preparation will be defined as a total BBPS score â?¥6 and each segment scores â?¥ 2.

Secondary

MeasureTime frame
Patientâ??s compliance and acceptabilityTimepoint: Compliance will be scored on a 3-grade scale according to the percentage of total solution intake (â?¥ 75% will be considered as adequate). Acceptability will be assessed by easiness of bowel preparation intake and percentage of patients willing to repeat it in future if needed .;Patientâ??s safetyTimepoint: Safety will be assessed by occurrence of new or increase in severity of preexisting gastrointestinal symptoms after bowel preparation intake.

Countries

India

Contacts

Public ContactManjit Kanungo

Department of Gastroenterology, Andhra Medical College

lrsgirinadh75@gmail.com9437082170

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026